Concepts (210)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Hepacivirus | 7 | 2019 | 1509 | 0.79 | Why? |
| Extracellular Traps | 2 | 2021 | 1036 | 0.58 | Why? |
| Sexually Transmitted Diseases, Viral | 1 | 2017 | 115 | 0.58 | Why? |
| Hepatitis C | 5 | 2018 | 1514 | 0.56 | Why? |
| Viral Envelope Proteins | 6 | 2020 | 3539 | 0.45 | Why? |
| Hepatitis C, Chronic | 4 | 2019 | 973 | 0.34 | Why? |
| Netherlands | 10 | 2021 | 3533 | 0.33 | Why? |
| Biosensing Techniques | 1 | 2021 | 2116 | 0.32 | Why? |
| Evolution, Molecular | 3 | 2017 | 3691 | 0.31 | Why? |
| Homosexuality, Male | 4 | 2018 | 1158 | 0.30 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2021 | 13720 | 0.29 | Why? |
| Genetic Variation | 3 | 2020 | 3919 | 0.27 | Why? |
| Molecular Diagnostic Techniques | 1 | 2020 | 4239 | 0.26 | Why? |
| Substance Abuse, Intravenous | 2 | 2019 | 411 | 0.26 | Why? |
| RNA, Viral | 11 | 2021 | 32276 | 0.25 | Why? |
| Molecular Epidemiology | 4 | 2017 | 1638 | 0.23 | Why? |
| Hepatitis C Antibodies | 2 | 2019 | 120 | 0.22 | Why? |
| Arterivirus | 1 | 2000 | 77 | 0.21 | Why? |
| Epitopes, B-Lymphocyte | 2 | 2019 | 1267 | 0.20 | Why? |
| DNA Primers | 2 | 2021 | 1170 | 0.19 | Why? |
| Viral Hepatitis Vaccines | 1 | 2019 | 58 | 0.19 | Why? |
| Clinical Laboratory Techniques | 3 | 2020 | 23402 | 0.19 | Why? |
| Cluster Analysis | 2 | 2017 | 3001 | 0.18 | Why? |
| Artifacts | 1 | 2020 | 250 | 0.18 | Why? |
| Transcription, Genetic | 2 | 2018 | 1326 | 0.16 | Why? |
| Yellow fever virus | 1 | 2019 | 205 | 0.16 | Why? |
| Organophosphonates | 1 | 2017 | 85 | 0.16 | Why? |
| Mink | 1 | 2020 | 399 | 0.16 | Why? |
| Insect Vectors | 1 | 2019 | 227 | 0.16 | Why? |
| Capsid | 1 | 1997 | 197 | 0.16 | Why? |
| Yellow Fever | 1 | 2019 | 231 | 0.15 | Why? |
| CD4-Positive T-Lymphocytes | 2 | 2021 | 4545 | 0.15 | Why? |
| Lectins, C-Type | 1 | 2018 | 405 | 0.14 | Why? |
| Cell Adhesion Molecules | 1 | 2018 | 472 | 0.14 | Why? |
| Gene Expression Regulation, Viral | 1 | 2000 | 925 | 0.14 | Why? |
| Health Services | 1 | 2021 | 765 | 0.14 | Why? |
| Adenine | 1 | 2017 | 463 | 0.14 | Why? |
| Cross Reactions | 3 | 2021 | 4374 | 0.14 | Why? |
| Genome, Viral | 5 | 2020 | 13157 | 0.13 | Why? |
| Receptors, Cell Surface | 1 | 2018 | 586 | 0.13 | Why? |
| CD8-Positive T-Lymphocytes | 2 | 2021 | 5837 | 0.13 | Why? |
| Tenofovir | 1 | 2017 | 449 | 0.13 | Why? |
| Sofosbuvir | 1 | 2018 | 518 | 0.13 | Why? |
| Sequence Alignment | 2 | 2017 | 2109 | 0.12 | Why? |
| Sequence Analysis, DNA | 3 | 2017 | 2830 | 0.12 | Why? |
| Limit of Detection | 1 | 2021 | 2698 | 0.12 | Why? |
| Polyethylene Glycols | 1 | 2017 | 574 | 0.12 | Why? |
| Virus Replication | 5 | 2014 | 14331 | 0.12 | Why? |
| Bronchoalveolar Lavage Fluid | 1 | 2021 | 2309 | 0.12 | Why? |
| Epithelial Cells | 2 | 2014 | 3508 | 0.11 | Why? |
| HIV Infections | 4 | 2018 | 11620 | 0.11 | Why? |
| Virus Cultivation | 1 | 2014 | 579 | 0.11 | Why? |
| Sensitivity and Specificity | 3 | 2021 | 22971 | 0.11 | Why? |
| HIV | 1 | 2017 | 1116 | 0.10 | Why? |
| Drug Resistance, Viral | 2 | 2018 | 1083 | 0.10 | Why? |
| Hepatitis B, Chronic | 1 | 2017 | 616 | 0.10 | Why? |
| Travel-Related Illness | 1 | 2017 | 1357 | 0.10 | Why? |
| Reagent Kits, Diagnostic | 1 | 2020 | 2149 | 0.10 | Why? |
| Viral Nonstructural Proteins | 3 | 2018 | 4810 | 0.10 | Why? |
| Phylogeny | 6 | 2020 | 13341 | 0.10 | Why? |
| Phenotype | 1 | 2020 | 4037 | 0.09 | Why? |
| Whole Genome Sequencing | 4 | 2020 | 3239 | 0.09 | Why? |
| Interferon-alpha | 1 | 2017 | 1442 | 0.09 | Why? |
| RNA, Messenger | 2 | 2000 | 5131 | 0.09 | Why? |
| Flow Cytometry | 1 | 2017 | 2393 | 0.09 | Why? |
| Murine hepatitis virus | 1 | 1997 | 1720 | 0.09 | Why? |
| Polymerase Chain Reaction | 2 | 2021 | 6740 | 0.09 | Why? |
| Oligopeptides | 1 | 2012 | 576 | 0.09 | Why? |
| Respiratory Tract Infections | 3 | 2018 | 6817 | 0.09 | Why? |
| Coronavirus | 4 | 2020 | 18339 | 0.09 | Why? |
| Community-Acquired Infections | 1 | 2020 | 2328 | 0.09 | Why? |
| Open Reading Frames | 3 | 2012 | 1898 | 0.08 | Why? |
| Longitudinal Studies | 3 | 2020 | 9893 | 0.08 | Why? |
| Cross Infection | 2 | 2020 | 8675 | 0.08 | Why? |
| Coronavirus Infections | 10 | 2020 | 253789 | 0.08 | Why? |
| Mutation, Missense | 1 | 2012 | 863 | 0.08 | Why? |
| Respiratory System | 3 | 2021 | 3213 | 0.08 | Why? |
| Zoonoses | 1 | 2020 | 3034 | 0.08 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.08 | Why? |
| Orthomyxoviridae | 1 | 2014 | 1168 | 0.08 | Why? |
| Viral Load | 4 | 2021 | 15850 | 0.08 | Why? |
| Respiratory Mucosa | 1 | 2014 | 1522 | 0.08 | Why? |
| Diarrhea | 1 | 2017 | 2743 | 0.07 | Why? |
| Humans | 33 | 2021 | 930598 | 0.07 | Why? |
| Viral Tropism | 1 | 2013 | 1329 | 0.07 | Why? |
| Mutation | 3 | 2021 | 12376 | 0.07 | Why? |
| Neutrophils | 1 | 2021 | 5476 | 0.07 | Why? |
| Virus Shedding | 1 | 2021 | 5834 | 0.07 | Why? |
| Coronavirus 229E, Human | 1 | 2012 | 1241 | 0.07 | Why? |
| Immunologic Memory | 3 | 2021 | 3362 | 0.07 | Why? |
| Genotype | 4 | 2018 | 4697 | 0.06 | Why? |
| Membrane Glycoproteins | 1 | 2012 | 2273 | 0.06 | Why? |
| Nasal Cavity | 1 | 2008 | 909 | 0.06 | Why? |
| Genetic Predisposition to Disease | 1 | 2018 | 4027 | 0.06 | Why? |
| Prospective Studies | 9 | 2021 | 43301 | 0.06 | Why? |
| Kinetics | 2 | 2021 | 3238 | 0.06 | Why? |
| Pneumonia, Viral | 6 | 2020 | 243684 | 0.06 | Why? |
| Cytokines | 2 | 2021 | 15010 | 0.06 | Why? |
| RNA Viruses | 1 | 2008 | 824 | 0.05 | Why? |
| Critical Illness | 2 | 2021 | 17281 | 0.05 | Why? |
| Cells, Cultured | 3 | 2020 | 5835 | 0.05 | Why? |
| Virus Diseases | 1 | 2018 | 3779 | 0.05 | Why? |
| Middle Aged | 15 | 2021 | 270681 | 0.05 | Why? |
| RNA-Directed DNA Polymerase | 1 | 2020 | 170 | 0.05 | Why? |
| Travel | 1 | 2019 | 7220 | 0.05 | Why? |
| DNA Probes | 1 | 2020 | 178 | 0.05 | Why? |
| Mutagenesis, Site-Directed | 1 | 2000 | 449 | 0.05 | Why? |
| Gambia | 1 | 2019 | 145 | 0.05 | Why? |
| Farms | 1 | 2020 | 269 | 0.05 | Why? |
| Male | 16 | 2021 | 367725 | 0.05 | Why? |
| Insect Bites and Stings | 1 | 2019 | 63 | 0.05 | Why? |
| Senegal | 1 | 2019 | 283 | 0.04 | Why? |
| Coinfection | 1 | 2018 | 6820 | 0.04 | Why? |
| Likelihood Functions | 1 | 2020 | 719 | 0.04 | Why? |
| Viruses | 1 | 2011 | 2238 | 0.04 | Why? |
| Point Mutation | 1 | 2000 | 481 | 0.04 | Why? |
| Hepatitis B e Antigens | 1 | 2017 | 99 | 0.04 | Why? |
| Pathology, Molecular | 1 | 2020 | 343 | 0.04 | Why? |
| Transgenes | 1 | 2017 | 227 | 0.04 | Why? |
| Parasitic Diseases | 1 | 2017 | 84 | 0.04 | Why? |
| Hepatitis B Antibodies | 1 | 2017 | 142 | 0.04 | Why? |
| Time Factors | 2 | 2017 | 31397 | 0.04 | Why? |
| Cell Separation | 1 | 2017 | 270 | 0.04 | Why? |
| Intention to Treat Analysis | 1 | 2017 | 673 | 0.04 | Why? |
| Fluorescence | 1 | 2017 | 475 | 0.04 | Why? |
| Liver Failure, Acute | 1 | 2019 | 279 | 0.04 | Why? |
| Hepatitis B Surface Antigens | 1 | 2017 | 305 | 0.04 | Why? |
| Spike Glycoprotein, Coronavirus | 3 | 2021 | 37182 | 0.04 | Why? |
| Chemokines | 1 | 2021 | 1095 | 0.04 | Why? |
| Antibodies, Neutralizing | 2 | 2019 | 25288 | 0.03 | Why? |
| Nucleocapsid Proteins | 2 | 2012 | 3120 | 0.03 | Why? |
| Antiviral Agents | 2 | 2018 | 41703 | 0.03 | Why? |
| Female | 11 | 2021 | 380317 | 0.03 | Why? |
| Adult | 12 | 2021 | 244371 | 0.03 | Why? |
| Disease Transmission, Infectious | 1 | 2017 | 9044 | 0.03 | Why? |
| Promoter Regions, Genetic | 1 | 2018 | 823 | 0.03 | Why? |
| Cell Line | 2 | 2021 | 12040 | 0.03 | Why? |
| Immunohistochemistry | 1 | 2021 | 2275 | 0.03 | Why? |
| Recombination, Genetic | 1 | 2000 | 1265 | 0.03 | Why? |
| Animals | 5 | 2020 | 78931 | 0.03 | Why? |
| Primary Cell Culture | 1 | 2014 | 501 | 0.03 | Why? |
| Genetic Drift | 1 | 2012 | 54 | 0.03 | Why? |
| Young Adult | 7 | 2020 | 93724 | 0.03 | Why? |
| Enterovirus Infections | 1 | 2017 | 404 | 0.03 | Why? |
| Cytopathogenic Effect, Viral | 1 | 2014 | 635 | 0.03 | Why? |
| Respiration, Artificial | 1 | 2018 | 22116 | 0.03 | Why? |
| Asthma | 1 | 2011 | 4383 | 0.03 | Why? |
| Lung | 1 | 2021 | 31049 | 0.03 | Why? |
| Hospitals, Teaching | 1 | 2020 | 1609 | 0.03 | Why? |
| Aged | 8 | 2021 | 215776 | 0.03 | Why? |
| Enterobacteriaceae Infections | 1 | 2017 | 529 | 0.03 | Why? |
| 3' Untranslated Regions | 1 | 2012 | 318 | 0.03 | Why? |
| Computed Tomography Angiography | 1 | 2021 | 2153 | 0.03 | Why? |
| Intensive Care Units | 1 | 2018 | 29594 | 0.03 | Why? |
| Alanine Transaminase | 1 | 2017 | 1329 | 0.03 | Why? |
| Waste Water | 1 | 2021 | 2185 | 0.03 | Why? |
| Delayed Diagnosis | 1 | 2020 | 1529 | 0.03 | Why? |
| Health Personnel | 1 | 2020 | 29646 | 0.03 | Why? |
| DNA Mutational Analysis | 1 | 2012 | 581 | 0.02 | Why? |
| Hepatitis B virus | 1 | 2017 | 882 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2021 | 5440 | 0.02 | Why? |
| Mice | 2 | 2000 | 21357 | 0.02 | Why? |
| Odds Ratio | 1 | 2021 | 5861 | 0.02 | Why? |
| Influenza B virus | 1 | 2014 | 815 | 0.02 | Why? |
| Severity of Illness Index | 3 | 2021 | 48226 | 0.02 | Why? |
| Diagnostic Tests, Routine | 1 | 2020 | 2643 | 0.02 | Why? |
| Antibodies, Viral | 1 | 2021 | 51949 | 0.02 | Why? |
| High-Throughput Screening Assays | 1 | 2017 | 1783 | 0.02 | Why? |
| Pandemics | 6 | 2020 | 389249 | 0.02 | Why? |
| Kaplan-Meier Estimate | 1 | 2018 | 4260 | 0.02 | Why? |
| Exhalation | 1 | 2011 | 441 | 0.02 | Why? |
| Laboratories | 1 | 2020 | 2858 | 0.02 | Why? |
| Disease Outbreaks | 3 | 2020 | 27595 | 0.02 | Why? |
| Adaptive Immunity | 1 | 2019 | 2585 | 0.02 | Why? |
| Recombinant Proteins | 1 | 2017 | 3786 | 0.02 | Why? |
| Clinical Decision-Making | 1 | 2020 | 3755 | 0.02 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 7868 | 0.02 | Why? |
| Cohort Studies | 2 | 2021 | 36005 | 0.02 | Why? |
| Amino Acid Substitution | 1 | 2012 | 1706 | 0.02 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2018 | 3607 | 0.02 | Why? |
| Base Sequence | 1 | 2012 | 3581 | 0.02 | Why? |
| Molecular Sequence Data | 1 | 2009 | 3198 | 0.02 | Why? |
| Antibody Formation | 1 | 2017 | 4038 | 0.02 | Why? |
| HEK293 Cells | 1 | 2017 | 8394 | 0.02 | Why? |
| Neutralization Tests | 1 | 2017 | 6698 | 0.02 | Why? |
| Feces | 1 | 2017 | 4235 | 0.02 | Why? |
| Europe | 1 | 2020 | 12702 | 0.02 | Why? |
| Follow-Up Studies | 2 | 2012 | 17020 | 0.02 | Why? |
| Sputum | 1 | 2011 | 1720 | 0.02 | Why? |
| High-Throughput Nucleotide Sequencing | 1 | 2014 | 3633 | 0.02 | Why? |
| Influenza A virus | 1 | 2014 | 2234 | 0.01 | Why? |
| Recurrence | 1 | 2011 | 3675 | 0.01 | Why? |
| Amino Acid Sequence | 1 | 2012 | 6049 | 0.01 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2020 | 11367 | 0.01 | Why? |
| Mass Screening | 1 | 2020 | 8005 | 0.01 | Why? |
| Thrombosis | 1 | 2021 | 7504 | 0.01 | Why? |
| Acute Kidney Injury | 1 | 2019 | 5762 | 0.01 | Why? |
| Biomarkers | 1 | 2021 | 23361 | 0.01 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.01 | Why? |
| Prevalence | 1 | 2017 | 25773 | 0.01 | Why? |
| Public Health | 1 | 2020 | 16359 | 0.01 | Why? |
| Aged, 80 and over | 2 | 2018 | 88759 | 0.01 | Why? |
| Incidence | 1 | 2015 | 25622 | 0.01 | Why? |
| Adolescent | 2 | 2017 | 86841 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2020 | 53120 | 0.01 | Why? |
| Case-Control Studies | 1 | 2011 | 17671 | 0.01 | Why? |
| Nasopharynx | 1 | 2011 | 10224 | 0.01 | Why? |
| Hospitalization | 1 | 2021 | 54280 | 0.01 | Why? |
| Retrospective Studies | 1 | 2015 | 105322 | 0.00 | Why? |
| Child | 1 | 2008 | 70012 | 0.00 | Why? |